Catalyz is developing affordable diagnostic and care systems for infectious and chronic diseases. The tests need no technical knowledge or any device to interpret the result, hence making it easy for a lame man in confirming or ruling out certain diseases.
Under this deal, Indoco will develop, manufacture and supply a number of products that have total yearly sales of $679 million at present.
Indias First Healthcare, Beauty & Wellness Franchising Report launched by Franchise India at the Kno
Franchise India Holdings limited in association with Francorp and Medium Healthcare Consulting Pvt Ltd has organized a two day workshop on Business of Healthcare, Wellness and Beauty at Taj Lands End, Mumbai. On the occasion India’s First Healthcare, Wellness and Beauty Franchising Report was launched by Mr. Ratan Jalaan, Founder, Medium Healthcare Marketing and Mr. Sachin Marya, CEO & Publisher, Franchise India Holdings Limited.
Union Health and Family Welfare Minister Ghulam Nabi Azad and Gujarat Chief Minister Narendra Modi, on Saturday invited expatriates to invest in the country.
Citing people familiar with the matter, pharmaquest.biz reported that Glaxo will take a 20-per cent stake in Dr. Reddy's Holdings Ltd., a family vehicle that owns 23.2 per cent of the Hyderabad-based Dr Reddy's Laboratories.
As domestic pharma and life science companies aggressively scale up their R&D capabilities to meet the rising demand for clinical research from global majors, they are back in the job market to scout and woo talent with attractive salary packages.
Bafna Pharmaceuticals,shall be focussing mainly on life-style products, the company chariman and managing director, Mahaveer Chand, disclosed, in an exclusive interview with pharmaquest.biz
Domestic drug companies, who have been challenging drug patents in the US and Europe, are now taking the first steps to challenge patents granted in India to companies based there.
Strides Acrolabs, which struck a drug supply deal with Pfizer on Wednesday, said it is discussing similar drug supply deal for niche therapeutics areas with global drug pharma companies. The Bangalore-based company will start getting part of the money from its deal with Pfizer this quarter onwards and that such deals would drive its future growth, a senior company executive said.
In one stroke, Swiss pharma giant Novartis AG could break into the league of top five players in the Rs 600-crore plus Indian eyecare market from its current position at 13, if its takeover of Alcon goes through seamlessly and eventually results in integration of Alcon India into the Indian arm of Novartis. Such a combined entity of Novartis and Alcon would then command a marketshare of 7.5% in the domestic eyecare market, just 1.4% less compared with the third and fourth ranked companies, FDC and Sun Pharma, which command 8.9% marketshare each.
The pharmaceutical market in Russia managed to grow by more than 25% in 2009 despite the economic downturn. But domestic producers are still losing out to their foreign rivals.
The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement Pfizer put out describing the deal.
* At least $1 billion incremental gains in export expected by 2014 Pakistan’s pharmaceutical sector has the potential to double its export in next five years provided pricing and contracting challenges are addressed in an efficient way, according to a draft of an official study.
Pharmaceutical major Piramal Healthcare is planning to raise Rs 1,000 crore (Rs 10 billion) in the next 6-8 months, a senior company official said here on Thursday.
Ahmedabad-based Cadila Healthcare Ltd could well be the first Indian company to launch the H1N1 vaccine in India. It expects to bring its vaccine in the market by April 2010.
The domestic pharmaceutical industry has urged the government to withdraw a study launched by the World Health Organization (WHO) in consultation with the Union ministry of health on implementing 'Data Exclusivity' in India.
The government will examine Sun Pharma’s post marketing surveillance studies (PMS) and clinical trials report of breast cancer medicine Letrox (chemical name letrozole) to decide whether the drug should be banned from being marketed, as an anti-infertility drug among young women.
Dishman Chemicals and Pharmaceuticals, the Ahmedabad-based leading player in the contract research and manufacturing services (Crams) space, is expecting growth of about 20% in the segment starting next fiscal.
The year had just begun, when Pfizer announced its $68-billion deal to acquire Wyeth, in January. On its heels came Merck & Co's $ 41-billion deal to acquire Schering-Plough Corporation, in March.
TCG Lifesciences, the Rs 400-crore clinical research organisation (CRO) venture of the Chatterjee Group, has entered into an exclusive collaboration with the US-based pharma giant, Pfizer, to develop a portfolio of pre-clinical molecules for discovery of new drugs.